WMH

🇹🇼🦋🐞🐛🌏 Nature lover/ Insect enthusiast/Butterfly collector and breeder

[WMH @WMaraho]

豔紅寬尾，十年一遇😆

[WMH @WMaraho]

An epic moment😎

[WMH @WMaraho]

@steamedchiken Aha, I guess I should ask my ophthalmologist colleagues for that.😅

[蒸し鶏屋 @steamedchiken]

ええ蝶や。

[あまげ @mushi_yahhoi64]

最高の色彩だ、、、

[WMH @WMaraho]

Atrophaneura hageni female

[WMH @WMaraho]

Try to relax these Atrophaneura with humid box

[みがし @Nesimachus]

Actias dubernardi
深夜に多数飛来。かっこよすぎる

[eudamippus @Ch_durnfordi]

Graphium phidias
フィディアス再び

[正直屋珍虫堂 @pidonia1171]

エエの採れた。

[WMH @WMaraho]

Graphium mullah chungianus

[柳澤 静磨 （ゴキブリスト） @UABIrurigoki]

フィリピンではカタゾウムシたちにもたくさん出会うことができました。

こんなすごいデザインの虫が地球にはたくさんいる。他にどんな模様がいるんだろうと考えながら探索するのは楽しすぎました。

[WMH @WMaraho]

Amblopala avidiena y-fasciata

[蒸し鶏屋 @steamedchiken]

今回の主目的、Actias neidhoeferiの雌。
本属最小種、高地棲なのに周年発生、そしてConifer feederなのにPinus属は利用しない。
見た目、生態、珍品度の三拍子が揃った非常に魅力的な種。
飛来した時は1人で叫んだ。

[WMH @WMaraho]

Papilio syfanius
Spring from top 2
Summer form bottom

[WMH @WMaraho]

Papilio machaon verityi
Papilio machaon verityi➡️
Papilio machaon archias⬅️

[Yakup Ergün @dr_yakupergun]

Emerging landscape of KRAS inhibitors in cancer treatment
https://t.co/8MI8BQStj0

[Dr Rishabh Jain @DrRishabhOnco]

🧬 KRAS is no longer “undruggable”.
A new Cancer Cell review maps how KRAS inhibitors are reshaping therapy across lung, colorectal, pancreatic and other cancers, and what comes next.

🔬 Essentials
• RAS alterations drive ~20% of cancers worldwide
• KRAS is the most frequent RAS alteration
• KRAS G12C inhibitors proved direct RAS targeting works

💊 Current reality
🟢 Sotorasib & adagrasib show meaningful activity in KRAS G12C NSCLC
🟢 CRC responses improve when combined with anti-EGFR therapy
🟢 Activity emerging in PDAC and other tumors

⚠️ Key challenge
Most patients eventually develop resistance via:
• On-target KRAS mutations
• MAPK pathway reactivation
• RTK feedback signaling
• Non-genetic adaptive escape

🚀 What’s next?
Next-generation strategies include:
• More potent G12C inhibitors
• KRAS G12D & multi-mutation inhibitors
• Isoform-selective and pan-RAS inhibitors
• Rational combination approaches

Takeaway: KRAS targeting has moved from breakthrough to optimization phase, with broader RAS inhibition now the next frontier.

📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #LungCancer #CRC @OncoAlert @myesmo @esmo_open @ASC